Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PEPD | P12955 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18193416 | 0.96 | MEN1 (0.35) | PEPDMEN1BLMKMT2ASLC1A2 | |
| SCHEMBL14944771 | 0.78 | GABRR1 (0.40) | MEN1BLMKMT2ASLC1A2SLC1A1 | |
| SCHEMBL11447722 | 0.75 | — | — | |
| SCHEMBL9978242 | 0.75 | SLC6A2 (0.38) | — | |
| SCHEMBL27844506 | 0.74 | HPGD (0.44) | KMT2AALDH1A1LMNA | |
| SCHEMBL8969423 | 0.74 | PEPD (0.41) | PEPDMEN1BLMKMT2AACE | |
| SCHEMBL8086372 | 0.74 | PEPD (0.41) | PEPDMEN1BLMKMT2AACE | |
| SCHEMBL12364331 | 0.74 | GABRR1 (0.37) | MEN1KMT2ASLC1A2SLC1A1LMNA | |
| SCHEMBL8969916 | 0.74 | PEPD (0.41) | PEPDMEN1BLMKMT2AACE | |
| SCHEMBL31387966 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729077-B2 | Anti-viral compounds, compositions, and methods of use | GLAXOSMITHKLINE LLC (US) | 2014-05-20 | — | — | US | disclosed |
| US-20110224211-A1 | Anti-Viral Compounds, Compositions, And Methods Of Use | GLAXOSMITHKLINE LLC | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224211-A1 | Anti-Viral Compounds, Compositions, And Methods Of Use | HAVCR2, SARS1, MAVS | PEPD 531/4885MEN1 3383/4885BLM 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.